Vaxcyte, Inc.
PCVX
$30.68
-$1.62-5.00%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | 226.16% | 226.16% |
| Gross Profit | -- | -- | -- | -226.16% | -226.16% |
| SG&A Expenses | 56.05% | 56.62% | 53.05% | 48.52% | 47.74% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 22.86% | 24.36% | 21.69% | 68.76% | 90.17% |
| Operating Income | -22.86% | -24.36% | -21.69% | -68.76% | -90.17% |
| Income Before Tax | -10.12% | -16.67% | -15.33% | -69.49% | -87.78% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -10.12% | -16.67% | -15.33% | -69.49% | -87.78% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -10.12% | -16.67% | -15.33% | -69.49% | -87.78% |
| EBIT | -22.86% | -24.36% | -21.69% | -68.76% | -90.17% |
| EBITDA | -21.90% | -23.44% | -21.01% | -68.75% | -90.63% |
| EPS Basic | 11.12% | 5.69% | 6.81% | -37.84% | -39.23% |
| Normalized Basic EPS | 11.12% | 5.69% | 6.81% | -37.87% | -39.26% |
| EPS Diluted | 11.12% | 5.69% | 6.81% | -37.84% | -39.23% |
| Normalized Diluted EPS | 11.12% | 5.69% | 6.81% | -37.87% | -39.26% |
| Average Basic Shares Outstanding | 22.50% | 23.65% | 25.58% | 24.72% | 33.17% |
| Average Diluted Shares Outstanding | 22.50% | 23.65% | 25.58% | 24.72% | 33.17% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |